Recludix Pharma, a leader in discovery of inhibitors of challenging targets for inflammatory disease, today announced that ...

Scientists at the Garvan Institute of Medical Research have uncovered a connection between certain genetic variations and the ...

The combination of ACT001 and radiotherapy elicited responses and was considered well tolerated in a phase 2 trial of pediatric patients with newly diagnosed DIPG.

Lead researcher, Dr Aleks Guanizo explained: "We identified a cascade in which the protein STAT3 is essential to maintain the ...

In 2023, we published another article about CRSP in Cell Biology Education – A Journal of Life Science Education. That article assesses the impact of shifting research modalities and their impacts on ...

Researchers have unlocked a key in a person's immune response that could halt the spread of cancer the body cannot see.

Bio-Path Holdings Inc (BPTH) reports progress in clinical trials and improved financial performance despite cash reserve ...

IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in HS and AD to ...

The following is a summary of “Allergic fungal rhinosinusitis linked to other hyper-IgE syndromes through defective TH17 ...

Expands DNAbilize® Technology Beyond Oncology into Obesity Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotech ...

Expands DNAbilize® Technology Beyond Oncology into ObesityConference Call to be Held Today at 8:30 A.M. ETHOUSTON, Nov. 15, 2024 (GLOBE ...

A groundbreaking approach slows tumor growth while boosting the immune system’s defense against cancer cells. Prostate cancer ranks as the second most common cancer among men globally. Despite recent ...